<DOC>
	<DOCNO>NCT00927186</DOCNO>
	<brief_summary>The purpose study investigate teriparatide zoledronic acid affect bone postmenopausal osteoporotic woman 6 month treatment determine bone biopsy sample take iliac crest ( upper part pelvis ) . After complete 12 month treatment participant eligible participate additional 12-month open label extension .</brief_summary>
	<brief_title>Effects Teriparatide Zoledronic Acid Treatment Bone Postmenopausal Osteoporotic Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Ambulatory , postmenopausal woman osteoporosis ( vaginal bleeding least 2 year prior trial entry ) Free severe chronically disable condition osteoporosis impair ability complete trial Bone mineral density ( BMD ) Tscore least 2.5 femoral neck , total hip , lumbar spine ( L1L4 , least 2 evaluable vertebra ) , without atraumatic fracture , Bone mineral density ( BMD ) Tscore least 1.5 femoral neck , total hip , lumbar spine ( L1L4 , least 2 evaluable vertebra ) , either 1 atraumatic vertebral fracture ( ) atraumatic nonvertebral fracture opinion investigator . Nonvertebral fracture sit allow wrist , hip , pelvis , rib , humerus , clavicle , leg ( femur , tibia , fibula , exclude ankle ) . Serum calcium , parathyroid hormone ( PTH ) , alkaline phosphatase must within normal reference range Have increase risk osteosarcoma ( bone tumor ) ; include Paget 's disease bone , previous bone tumor , radiation involve skeleton Are allergic tolerate teriparatide zoledronic acid ingredient component Are allergic tetracycline Have history exposure tetracycline therapy 3 month prior trial entry Have participate prior PTH clinical trial receive prior treatment teriparatide , PTH , related medication Have vitamin D level 10 nanogram/milliliter ( ng/mL ) Have condition could possibly put one risk adverse event due bone biopsy procedure ( e.g . bleed disorder ) Have undergo two previous iliac crest bone biopsy ( one iliac crest ) Have take intravenous ( IV ) osteoporosis medication Have take oral osteoporosis medication specific period time trial entry Have history certain cancer 5 year prior trial entry Have active liver disease Have significantly impair kidney function Currently active suspect disease affect bone , osteoporosis Have active recent history significant gastrointestinal ( stomach intestinal ) disorder Have treat certain glucocorticoid 30 day past 1 year prior trial entry</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>teriparatide</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>histomorphometry</keyword>
	<keyword>bone biopsy</keyword>
	<keyword>postmenopausal</keyword>
</DOC>